VIDEO: Expert discusses CLL highlights from ASH
Click Here to Manage Email Alerts
LOXO-305, a novel non-covalent BTK inhibitor, was active in B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, according to data presented at the ASH Annual Meeting and Exposition.
“Both of these studies showed that LOXO-305 is well-tolerated and clinically active in B-cell malignancies, including both CLL and mantle cell lymphoma patients who had been previously treated with traditional covalent BTK inhibitors,” Brian T. Hill, MD, PhD, of Cleveland Clinic, told Healio in a video interview.
Hill also discussed abstracts on combination treatment in CLL presented at the meeting.
“We’re well into the targeted therapy era in CLL,” he said. “We’ve seen that BTK inhibitors and BCL-2 inhibitor venetoclax are independently both very active agents and we’ve seen that they are safe to combine.”
Phase 2 data from the CAPTIVATE study showed that a very high proportion of patients with CLL who received ibrutinub plus venetoclax reached an undetectable MRD state, according to Hill.
“I think the message here is that we’re getting closer to the potential for a defined time limited therapy for CLL in which we don’t necessarily need to continue these agents indefinitely because doing so is often associated with significant cost as well as potential for toxicities and side effects,” Hill said.
Collapse
Mato AR, et al. Abstract 542. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Wang M, et al. Abstract 117. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Wierda WG, et al. Abstract 123. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Click Here to Manage Email Alerts